Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group

作者
David Arias Ron,María Carmen Areses Manrique,Joaquín Mosquera,Jorge García,Francisco Javier Afonso Afonso,Martín Lázaro Quintela,Natalia Fernández Núñez,Cristina Azpitarte Raposeiras,Margarita Amenedo,Lucía Santomé Couto,M.R. García Campelo,Jose Muñoz Iglesias,Juan Ruiz Bañobre,Rocío Vilchez Simó,Joaquin Casal Rubio,B. Campos Balea,Iria Carou,Guillermo Alonso-Jáudenes Curbera,Urbano Anido Herranz,Jesús García Mata
出处
期刊:Journal of Geriatric Oncology [Elsevier BV]
卷期号:12 (3): 410-415 被引量:7
标识
DOI:10.1016/j.jgo.2020.11.010
摘要

BACKGROUND: Nivolumab is an anti PD1 immunotherapy drug approved for advanced Non-Small Cell Lung Cancer (NSCLC) patients who previously received at least one prior line of treatment. Older patients are often not represented in clinical trials and drugs with acceptable safety profiles are necessary. We aim to report the efficacy and safety profile of Nivolumab in the real-world older subgroup of the Galician lung cancer group study. PATIENTS AND METHODS: We retrospectively reviewed 188 advanced NSCLC patients treated with at least one prior therapy. We collected data from patients who were ≥70 years old treated with Nivolumab in second or subsequent lines. Patient characteristics, treatment efficacy (overall survival, progression-free survival, and response rate), and safety profile were reported. RESULTS: Thirty-eight patients aged ≥70 years were included in the subgroup analysis. The median age was 74.5 years, a high percentage of patients were males (95%), most had a Performance Status of 1 (79%) and only 13% were non-smokers. The predominant histology was adenocarcinoma (53%), and 18% of patients received 2 or more lines. The median Progression-Free Survival was 7.53 months (CI 4.3-17.3, p = 0.15) and the median Overall Survival was 14.85 months (CI 10.5-20.7, p = 0.44). The objective response rate was 42%. No new adverse events were reported in comparison to a global population. CONCLUSIONS: The efficacy and safety profile of Nivolumab in advanced NSCLC patients treated with at least one prior therapy and age ≥70 years old can be overlapped to a global population. Further prospective trials are needed to define and confirm these results.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刘一半相思完成签到,获得积分10
刚刚
小森林发布了新的文献求助10
刚刚
1秒前
JXnotme完成签到,获得积分10
1秒前
清爽老九发布了新的文献求助30
1秒前
殷硕完成签到,获得积分10
1秒前
文静的以松完成签到,获得积分10
1秒前
2秒前
sx完成签到,获得积分10
2秒前
小唐完成签到,获得积分10
2秒前
淡然妙松发布了新的文献求助10
2秒前
grs完成签到,获得积分10
2秒前
liuyang完成签到 ,获得积分10
2秒前
guantian完成签到,获得积分10
3秒前
ouen完成签到,获得积分10
3秒前
袁气奶豆完成签到,获得积分10
3秒前
Leo完成签到,获得积分10
3秒前
小柔完成签到,获得积分10
3秒前
xx完成签到,获得积分10
3秒前
朱海龙完成签到,获得积分10
4秒前
今后的应助被核磁共振经颅磁采纳,获得10
4秒前
雷子完成签到,获得积分10
4秒前
Dialectical发布了新的文献求助50
4秒前
sci高手完成签到,获得积分10
4秒前
DuanJN完成签到,获得积分10
5秒前
ocean完成签到,获得积分10
5秒前
momo完成签到 ,获得积分10
5秒前
开心乌冬面完成签到 ,获得积分10
5秒前
热心雪一完成签到,获得积分10
6秒前
思源的应助被qearl采纳,获得10
6秒前
6秒前
6秒前
活泼项链完成签到,获得积分20
6秒前
含蓄青旋完成签到 ,获得积分10
6秒前
Maxwell完成签到,获得积分10
6秒前
小月亮完成签到,获得积分10
6秒前
汉堡包的应助被自由棉花糖采纳,获得10
7秒前
7秒前
毋意发布了新的文献求助30
7秒前
小王发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570485
关于积分的说明 21812623
捐赠科研通 7776592
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557522
邀请新用户注册赠送积分活动 2479162